

1 **Plasma (1→3) β -d-glucan levels are associated with host inflammatory responses and predict**
2 **adverse clinical outcomes in critical illness.**

3
4 Georgios D. Kitsios, MD, PhD^{*1,2}; Daniel Kotok, MD^{*3}; Haopu Yang, MD^{c1,4,5}; Malcolm Finkelman, PhD⁶;
5 Yonglong Zhang MD, PhD⁶; Noel Britton, MS^{1,2}; Rui Guo¹; John W. Evankovich, MD¹, William Bain, MD¹;
6 Faraaz Shah, MD, MPH^{1,7}; Yingze Zhang, PhD¹; Panayiotis V. Benos, PhD⁷; Bryan J. McVerry, MD^{1,2};
7 Alison Morris, MD, MS^{1,2,8}

8
9 ¹Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of
10 Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA;

11 ²Center for Medicine and the Microbiome, University of Pittsburgh; ³Internal Medicine Residency Program,
12 University of Pittsburgh Medical Center McKeesport; ⁴School of Medicine, Tsinghua University, Beijing,
13 China; ⁵Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA;

14 ⁶Associates of Cape Cod, Inc, East Falmouth, MA, USA; ⁷Veteran Affairs Pittsburgh Healthcare System,
15 Pittsburgh, PA; ⁸Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA,
16 USA;

17
18 ***co-first authors**

19
20
21
22
23
24 Correspondence:

25 Georgios D. Kitsios, MD, PhD

26 Assistant Professor of Medicine

27 Division of Pulmonary, Allergy and Critical Care Medicine

28 UPMC Montefiore Hospital,

29 NW628 3459 Fifth Avenue, Pittsburgh, PA 15213

30 kitsiosg@upmc.edu

1

2 **Abstract**

3

4 **Background:** The fungal cell-wall constituent (1,3)- β -d-glucan (BDG) is a pathogen-associated molecular
5 pattern (PAMP) that can stimulate innate immunity. We hypothesized that BDG from colonizing fungi in
6 critically-ill patients may translocate into the systemic circulation and thus be associated with host
7 inflammatory responses and outcomes.

8

9 **Methods:** We enrolled 453 mechanically-ventilated patients with acute respiratory failure with no evidence
10 of invasive fungal infection (IFI). From serial plasma samples, we measured BDG, innate immunity and
11 epithelial permeability biomarkers. From lower respiratory tract and stool samples we quantified bacterial
12 and fungal DNA load using culture-independent techniques.

13

14 **Results:** A positive BDG test ($>60\text{pg/ml}$) at baseline was detected in 19% of patients. BDG levels were
15 significantly associated with markers of innate immunity (interleukin-6, tumor necrosis factor receptor-1 and
16 procalcitonin), epithelial barrier disruption (receptor for advanced glycation end-products and fatty-acid
17 binding protein-2, for lung and gut respectively) and with higher probability of classification in an adverse
18 prognosis hyperinflammatory subphenotype (all $p<0.05$). No differences in fungal or bacterial DNA load
19 were found by BDG test positivity. Positive BDG testing was associated with higher incidence of acute
20 kidney injury, fewer ventilator free days and worse 30-day survival (adjusted $p<0.05$). Patients with positive
21 BDG test on follow-up sampling (>3 days from intubation) had higher mortality than patients with
22 persistently negative test on follow-up ($p<0.05$).

23

24 **Conclusions:** This is the first study to demonstrate the prognostic role of BDG in critically ill patients with
25 no evidence of IFI. Translocation of BDG into systemic circulation may contribute to inflammation and
26 clinical outcomes.

27

28 Funding support: National Institutes of Health [K23 HL139987 (GDK); U01 HL098962 (AM); P01 HL114453
29 (BJM); R01 HL097376 (BJM); K24 HL123342 (AM); U01 HL137159 (DVM, PVB); R01 LM012087 (DVM,
30 PVB); R01 HL142084 (JSL); R01 HL136143 (JSL); F32 HL137258 (JWE); F32 HL142172 (WB); K08
31 HS025455 (IJB); K23 GM122069 (FS)].

1 **Keywords**

2 ARDS, Mycobiome, phenotype, glucans, critical illness

3

4 **List of abbreviations**

5 ARDS – Acute Respiratory Distress Syndrome

6 ALIR – Acute Lung Injury and Biospecimen Repository

7 AKI – Acute kidney injury

8 CHF – Congestive heart failure

9 ICU – Intensive care unit

10 IL – Interleukin

11 ITS – Internal transcribed spacer

12 IFI – Invasive fungal infection

13 P:F ratio – Ratio of partial pressure of arterial oxygen [P] and fraction of inspired oxygen [F]

14 RAGE – Receptor of advanced glycation end-products

15 SOFA – Sequential Organ Failure Assessment

16 ST-2 – Suppression of tumorigenicity-2

17 TNFR1 – Tumor necrosis factor receptor 1

18 UPMC – University of Pittsburgh Medical Center

19 VFD – Ventilator-free days

20

21

1 Introduction

2 Dysregulation of innate immunity is a central pathogenetic feature of the heterogeneous syndromes
3 of sepsis and the acute respiratory distress syndrome (ARDS) (1, 2). In several independent patient
4 populations, patient subgroups with elevated plasma levels of inflammatory cytokines and biomarkers of
5 tissue injury (classified as a *hyperinflammatory subphenotype*) exhibit worse organ dysfunction and clinical
6 outcomes compared to their *hypoinflammatory* counterparts (3–5). Such biologic subphenotyping of
7 critically-ill patients offers improved risk prediction over stratification with clinical variables alone, and
8 presents new opportunities for targeted pharmacologic interventions (6). However, the molecular
9 mechanisms of aberrant innate immunity stimulation and resultant tissue injury remain largely undefined.

10 Inter-patient variability of endogenous microbiota may explain the observed differences in host-
11 responses. Many of the predictive biomarkers for the detrimental hyperinflammatory subphenotype (e.g.
12 interleukins [IL]-6 and -8, soluble tumor necrosis factor receptor-1 [TNFR1], procalcitonin and receptor for
13 advanced glycation end-products [RAGE]) (3, 4) reflect canonical pathways of immune cell stimulation from
14 pathogen and damage associated molecular patterns (PAMPs and DAMPs, respectively) (7, 8). PAMPs
15 include microbial nucleic acids as well as cell wall components, such as lipopolysaccharide of gram-
16 negative bacteria and 1-3-beta-D-glucan (BDG) from fungi (8, 9). Recent culture-independent studies with
17 bacterial DNA sequencing have uncovered important roles of intestinal and respiratory bacterial
18 communities in the evolution and outcome of critical illness (10–13). However, very few studies have
19 performed in depth examinations of the fungal communities (mycobiome) in critical illness (14) and little is
20 known about how fungal PAMPs may interact with the innate immunity system in the critically-ill host.

21 Epidemiologic evidence suggests that host-fungal interactions at different mucosal surfaces are
22 clinically important (15). In mechanically-ventilated immunocompromised patients, airway colonization by
23 *Candida* species portends worse outcome (16), and in patients with suspected ventilator-associated
24 pneumonia, *Candida* species in respiratory tract secretions have been associated with increased mortality
25 and levels of IL-6 and procalcitonin (17, 18). *C.albicans* overgrowth in the human gut occurs in the setting
26 of antibiotic-treated sepsis, raising the risk for secondary candidemia (19, 20). The respiratory and intestinal
27 tracts in critical illness contain high levels of the fungal PAMP BDG. BDG is recognized by mucosal innate
28 immune cells through the dectin-1 receptor and stimulates local inflammatory responses (21). It can also
29 exert systemic effects on host inflammation via translocation into the bloodstream, in the setting of

1 disruption of mucosal epithelial integrity from various insults, such as hypoxemia, ischemia or direct
2 pathogen invasion (22). Preliminary observations have suggested that higher levels of circulating BDG are
3 associated with worse clinical outcomes in patients in the intensive care unit (ICU) (23), but evidence has
4 been limited. BDG levels are routinely checked in the diagnostic work-up of critically-ill patients with clinical
5 suspicion of invasive fungal infection (IFI) (24), but whether BDG could be used as a clinical biomarker of
6 fungal PAMP translocation and its contribution to the development and perpetuation of hyperinflammatory
7 host-responses in critical illness is unknown.

8 In this study, we demonstrate that approximately 20% of critically-ill patients without IFI have
9 elevated plasma BDG levels (as defined by a positive BDG test). Patients with a positive plasma BDG test
10 had higher levels of circulating biomarkers of innate immunity and tissue injury, were more likely to be
11 classified as the adversely prognostic hyperinflammatory subphenotype, and had worse clinical outcomes
12 independent of other prognostic factors. Exploratory analyses for the potential source of BDG e.g. the
13 intestinal or respiratory tract, suggested the potential presence of heterogeneous mechanisms underlying
14 fungal PAMP translocation in critical illness.

15 **Results:**

16 *Study population:* We analyzed data from 453 mechanically-ventilated patients with acute respiratory
17 failure, who were consecutively enrolled from ICUs at the University of Pittsburgh Medical Center (UPMC)
18 (3, 25). We excluded 11 patients with a clinical diagnosis of IFI (24) because we wanted to examine BDG
19 as a fungal PAMP in a broad ICU population and not in the context of IFI as a diagnostic test. However,
20 inclusion of patients with IFI in sensitivity analyses did not impact the observed associations and outcomes.
21 Characteristics of included patients are shown in Table 1.

22 *Distribution of plasma BDG levels in critically-ill patients:* At baseline, 85 patients (19%) had positive BDG
23 defined as greater or equal to the conventional threshold of 60 pg/ml (Figure 1) (24). Patients with positive
24 BDG levels (median 95, interquartile range [IQR] 76-227 pg/ml) had similar distribution of baseline clinical
25 characteristics as patients with negative BDG (median 26, IQR 15-49 pg/ml), with the exception of higher
26 sequential organ failure assessment (SOFA) scores in the positive group ($p=0.01$, Table 1). Similar results
27 were obtained when we used a more stringent threshold of BDG positivity (80 pg/ml, Table S1). Although
28 beta-lactam antibiotics have been previously implicated in false-positive BDG detection (26, 27), we did not
29 find any differences in BDG levels between patients receiving beta-lactam antibiotics, or not, at the time of

1 sampling. A small proportion of patients (2.9%) receiving topical antifungals for either oral thrush or skin
2 candidiasis (clotrimazole troche or nystatin) had significantly higher BDG levels compared to those not
3 receiving these medications (n = 13 [2.9%], p=0.03).

4 *Plasma BDG correlates with host-response biomarkers and the hyperinflammatory subphenotype: We*
5 systematically profiled host-responses by measuring plasma biomarkers in pathways of innate immunity
6 (IL-6, IL-8, IL-10, TNFR1, fractalkine, suppression of tumorigenicity-2 [ST-2]), alveolar epithelial injury
7 (RAGE), endothelial injury (angiopoietin-2) and response to bacterial infection (procalcitonin and pentraxin-
8 3) (3). BDG levels at baseline positively correlated with levels of all measured biomarkers (p<0.05), with
9 seven of these correlations remaining significant after adjustments for multiple testing (Figure 2A). We
10 synthesized these host-response profiles into a parsimonious regression model for classification into a
11 hyperinflammatory (28%) vs. a hypoinflammatory subphenotype (72%) based on latent class analyses as
12 previously described (3). Hyperinflammatory patients had significantly higher mean BDG levels than
13 hypoinflammatory ones (39 [23-68] vs. 23 [14-39] pg/ml, p<10⁻⁶, Figure 2B).

14 *Network analyses reveal association of BDG with key elements of the hyperinflammatory response. To*
15 comprehensively examine for causal associations between baseline clinical variables, biomarkers and
16 BDG, we utilized the Probabilistic Graphical Models (PGM) framework (3, 28, 29). From a total of 32
17 variables, only two were directly linked with BDG (i.e. first neighbors in PGM): TNFR1, a predictive
18 biomarker for the hyperinflammatory subphenotype, and ST-2, the soluble receptor of IL-33 that functions
19 as an alarmin released by respiratory epithelia during acute lung injury (30). Both TNFR1 and ST-2 were
20 further linked to additional components of the hyperinflammatory response (Figure 2C).

21 *Patients with higher BDG levels had worse clinical outcomes.* BDG levels analyzed as a continuous
22 variable were associated in regression models with higher incidence of acute kidney injury (AKI), fewer
23 ventilator-free days (VFDs) and higher 30-day mortality (all p<0.05, Table 2). These associations with
24 clinical endpoints remained significant after adjustments for other important predictors of outcome in critical
25 illness (age, SOFA scores and hyperinflammatory subphenotype) as well as potential confounders of BDG
26 measurement (beta-lactam antibiotics that have been associated with false positive BDG and batch of BDG
27 measurement). Patients with positive BDG testing had worse 30-day survival (adjusted hazard ratio: 1.37,
28 95% confidence interval 1.13-1.67, p<0.001) compared to patients with negative BDG (Figure 3).

1 *BDG is associated with markers of epithelial barrier disruption in the respiratory and intestinal tract.* Given
2 the clinically significant prognostic associations of BDG, we sought to understand potential sources of
3 plasma BDG and whether it is derived from intestinal or respiratory tract fungi. To that end, we examined
4 associations between plasma BDG with biomarkers of epithelial barrier disruption and differences in
5 microbial load (bacterial and fungal) in each body compartment studied by culture-independent techniques.

6 For the respiratory tract, plasma BDG levels were significantly associated with plasma levels of
7 RAGE ($p < 0.005$), a biomarker of alveolar epithelial injury. This association remained significant after
8 adjustment for clinical variables potentially related to fungal colonization in the airways (systemic antibiotics
9 and steroid administration on day of sampling). We directly quantified bacterial and fungal load in lower
10 respiratory tract communities (endotracheal aspirate samples) by quantitative polymerase chain reaction
11 (qPCR) of the bacterial 16S rRNA gene and by absolute number of reads (sequences) of the Internal
12 Transcribed Spacer (ITS) region sequencing of the fungal genome, respectively. BDG was not significantly
13 associated with bacterial (16S qPCR) or fungal load (number of ITS reads) in lower respiratory tract
14 samples. However, BDG remained significantly associated with RAGE ($p < 0.005$) after adjustment for
15 bacterial and fungal load, indicating that epithelial permeability may be a more important contributor to BDG
16 translocation rather than the absolute amount of fungi in the airways.

17 To examine the potential origin of BDG from the intestinal tract, we measured plasma levels of fatty
18 acid binding protein-2 (FABP-2), a validated biomarker of intestinal barrier integrity (31), in a random subset
19 of 220 patients. BDG levels were significantly associated with FABP-2 ($p < 0.05$, Figure 3), an association
20 that remained significant after adjustment for variables potentially related to intestinal tissue ischemia and
21 fungal overgrowth (administration of vasopressors and systemic antibiotics at time of sampling,
22 respectively). We did not find any significant association between plasma BDG and measurements of
23 fungal and bacterial load in stool samples in a small subset with available data ($n = 16$). Thus, integrative
24 analyses of biomarkers of epithelial disruption and microbial load suggested that the possibility that BDG
25 may translocate to the systemic circulation from both the respiratory and gastrointestinal tract.

26 *Longitudinal evolution of BDG levels and association with outcomes:* For 156 patients (34% of the cohort),
27 follow-up plasma samples were obtained in the time window from day 3 to 5 from baseline while the
28 patients remained in the ICU. Patients with a negative baseline test who developed a positive test on
29 follow-up ($N = 10$, 6%) and those with an initial positive test who had a subsequent negative test ($N = 17$,

1 11%) had worse 30-day mortality compared to patients who remained negative on follow-up ($p < 0.05$,
2 Figure 5).

4 **Discussion:**

5 We demonstrated that BDG is detectable in the plasma in 19% of mechanically ventilated patients
6 from a general ICU population. BDG levels correlated with host-response biomarkers of injury and
7 inflammation and independently predicted adverse clinical outcomes. Over time, patients with incident BDG
8 positivity had higher mortality than patients with persistently negative BDG testing. Significant associations
9 with markers of intestinal and respiratory tract epithelial permeability suggested the possibility of fungal
10 PAMP translocation from either vascular site, independent of fungal or bacterial loads.

11 BDG represents a highly immunostimulatory molecule that is likely to mediate the effects of
12 colonizing fungi in critically ill patients. As a constituent of the cell-wall of many potentially pathogenic fungi,
13 BDG is recognized by pattern recognition receptors such as complement receptor 3 and dectin-1 present
14 on the surface of macrophages, dendritic cells, neutrophils and pulmonary epithelial cells (21, 32–34). Co-
15 stimulation of dectin-1 with Toll-like receptors augments cytokine production via NF- κ B-dependent (nuclear
16 factor kappa-light-chain-enhancer of activated B cells) signaling (32, 34). Such innate immune responses,
17 albeit necessary for the recognition and clearance of invading fungi, may also lead to exacerbated mucosal
18 inflammation and injury upon perpetual and aberrant stimulation.

19
20 The role of BDG in the pathogenesis of mucosal injury and local inflammation, however, may not be
21 limited necessarily to that of a direct stimulant of the innate immune system. Fungal PAMPs in the form of
22 heat inactivated *Candida* were shown to reduce the killing activity of bone-marrow derived macrophages
23 while enhancing cytokine production (35), while intact *Candida* has been shown to reduce the phagocytic
24 abilities of macrophages (36), potentially by a soluble molecule (37) among other poorly understood
25 mechanisms. Such mechanisms can lead to impaired first-line defenses of mucosal immunity with
26 concurrent precipitation of host injury and inflammation either by fungi or other pathogenic microbes at
27 mucosal sites. Therefore, complex interactions between colonizing fungi, non-fungal members of the
28 microbial community and the critically-ill host need to be considered.

1 Dysregulation of host-responses with high levels of circulating inflammatory cytokines and immune
2 cell activation is a key pathogenetic feature in the evolution of critical illness (38). Unsupervised
3 classification analyses in patients with sepsis, severe pneumonia or ARDS have discovered the presence
4 of distinct subphenotypes, characterized by a hyperinflammatory vs. a hypoinflammatory cluster of host-
5 responses(3–5). The markedly worse outcomes and differential treatment responses associated with the
6 hyperinflammatory subphenotype offer a new framework for predictive enrichment and the delivery of
7 targeted efficacious therapies (e.g. anti-inflammatory drugs to be given only to patients with the
8 hyperinflammatory subphenotype who are likely to benefit) (6). However, the proximal, molecular
9 determinants of ARDS and sepsis subphenotypes have not been defined, and, similarly, clinical
10 stratifications by types of insult (e.g. pneumonia or extrapulmonary infection etc.) have not been informative
11 for distinguishing host-responses (3, 39). Thus, we posit that at least some of the observed host-response
12 heterogeneity may be accounted by host-microbial interactions. Beyond the well-recognized importance of
13 bacterial pathogens, translocating fungal PAMPS and their interactions with innate immune cells may also
14 significantly contribute to the evolution and outcome of critical illness.

15 Epidemiologic observations support the role of fungi in critical illness, even outside the context of
16 conventionally defined IFI. Evidence of *Candida* colonization in the airways or fungal overgrowth in the
17 gastrointestinal tract has been associated with worse clinical outcomes, including but not limited to the
18 development of serious bloodstream infections due to systemic invasion of fungi from different mucosal
19 surfaces (16, 17, 19, 20). Factors that have been associated with fungal colonization in critically-ill patients
20 include widespread antibiotic use, which allow fungi to grow and overtake environmental niches (20), as
21 well as primary or iatrogenic immunosuppression, such as with inhaled corticosteroid therapies leading to
22 upper respiratory tract fungal colonization (40). Our study utilized culture-independent methods (BDG
23 measurement and next-generation sequencing approaches) to examine for translocation of fungal elements
24 into the blood stream, their interactions with innate immunity and prognostic importance in a broad ICU
25 population with no clinical evidence of IFI.

26 We observed associations of circulating BDG with innate immune responses as well as biomarkers
27 of epithelial permeability in the respiratory and intestinal tract. BDG may be stimulating innate immunity not
28 only through mucosal interactions, but also in the bloodstream and in tissue locations within the
29 reticuloendothelial system (35, 41). Therefore, circulating BDG molecules may not simply represent a
30 marker of mucosal barrier injury that has found its way into the bloodstream, but also an active mediator of

1 inflammatory organ dysfunction and illness severity in sepsis (9, 35). Our integrative analyses of
2 permeability biomarkers and culture-independent assays of bacterial/fungal load did not reveal a specific
3 primary source of circulating BDG from either the lungs or the gut. However, we identified significant
4 independent associations of BDG with corresponding markers of epithelial permeability in both
5 compartments. With regards to the lungs, soluble RAGE, an extensively validated biomarker of ARDS
6 radiographic and clinical severity (25, 42, 43), was strongly associated with plasma BDG levels, potentially
7 reflecting the degree of pulmonary epithelial/endothelial disruption and ability of BDG from airway
8 colonizing fungi to enter the systemic circulation. Similarly for the gut, BDG levels were also associated with
9 FABP2, a biomarker of intestinal barrier disruption (31). In animal models of intestinal leakage via direct
10 physical or chemical injury, serum BDG testing showed low sensitivity but high specificity for a permeable
11 gut (44). Direct measurement and study of the phenomenon of microbial translocation in human
12 translational studies is challenging, and no gold-standard method exists for *in vivo* study (45). Thus, blood
13 levels of BDG may offer a non-invasive and clinically available surrogate measure of gut/lung permeability
14 in critically ill patients, with important prognostic implications.

15 A positive BDG test (defined as >60pg/ml) conferred an adverse prognosis in our inclusive cohort of
16 subjects with acute respiratory failure. BDG-positive patients demonstrated higher severity of illness by
17 SOFA score, accumulated more severe organ dysfunction (incident AKI and fewer VFDs) and had
18 significantly worse 30-day survival. These associations with adverse outcomes remained significant after
19 multivariate model adjustments for age, severity of illness and host-response subphenotypes, suggesting
20 that BDG testing may capture prognostic information not offered by clinically available and emerging
21 stratification tools based on biomarkers. Similar observations of poor prognosis associated with BDG had
22 been reported in smaller cohorts of patients with suspected VAP as well as in patients with sepsis (23, 44).
23 Our findings in a much larger and inclusive cohort suggest that BDG may offer additional prognostic
24 information in the course of critical illness. Further validation of the prognostic utility of BDG in independent
25 cohorts is needed.

26 Our study has several limitations. It is a single-center study, and the generalizability of our findings
27 in critically ill populations beyond our tertiary care ICU requires external validation. Our study is also limited
28 by the available sample size. Despite being the largest study of BDG measurement in acute respiratory
29 failure, results from analyses for subgroups and specific biomarkers (e.g. FABP2) require cautious
30 interpretation, as the effective sample size for certain analyses was smaller. Although we aimed to control

1 for potential confounders of BDG measurement from available variables (batch of measurement, beta-
2 lactam antibiotics or bacteremia), there may be other sources of BDG false positivity, such as hemodialysis
3 or blood product preparation filter processing that were not possible to account for in our analyses (46, 47).
4 Finally, the extent of microbiologic workup for diagnosis of bacterial infection or IFI was directed by the
5 treating physicians and, as such, microbiologic testing was not uniform. Thus, it is possible that some of the
6 BDG positive cases may represent clinically undiagnosed or preclinical IFI. Nonetheless, inclusion of
7 patients with IFI in sensitivity analyses did not impact the observed associations.

8 In summary, we demonstrate that circulating BDG is an independent predictor of a
9 hyperinflammatory host-response profile and adverse clinical outcomes in mechanically ventilated patients
10 with acute respiratory failure. These associations highlight a novel, underappreciated mechanism of
11 biological heterogeneity in critical illness that involves interactions between translocating fungal PAMPs and
12 innate immunity, which is independent of fungal load at mucosal sites and points towards complex
13 interactions between the host, fungi and other microbes. Our findings call for further mechanistic
14 interrogation in animal studies and independent prospective clinical study to validate the biologic relevance
15 and prognostic information of circulating BDG.

17 **Methods:**

18 Clinical cohort and sample collection:

19 From October 2011 – June 2019, we prospectively enrolled a convenience sample of consecutive,
20 adult patients with acute respiratory failure, who were intubated and mechanically-ventilated in the Medical
21 or Cardiac Intensive Care Units (ICU) at the University of Pittsburgh Medical Center. Exclusion criteria
22 included inability to obtain informed consent, presence of tracheostomy, or mechanical ventilation for more
23 than 72 hours prior to enrollment. The study was approved by the University of Pittsburgh Institutional
24 Review Board (protocol PRO10110387), and written informed consent was provided by all participants or
25 their surrogates.

26 From enrolled subjects, we collected blood samples for centrifugation and separation of plasma and
27 serum. We also collected noninvasive biospecimens for study of lower respiratory tract microbiota with

1 endotracheal aspirates (ETA) and we analyzed stool samples for study of the intestinal microbiota, as
2 previously described (48, 49).

3 Laboratory analyses:

4 We measured plasma BDG levels using the commercially available Fungitell® Limulus Amebocyte
5 Lysate (LAL) assay (Associates of Cape Cod, Inc, East Falmouth, MA, USA) at the manufacturer's facility
6 (50). As a biomarker of intestinal permeability, we measured levels FABP2 with the Quantikine® Human
7 FABP2/I-FABP Immunoassay (R&D Systems, Minneapolis, USA). For profiling host-responses, we
8 constructed a custom Luminex multi-analyte panel (R&D Systems, Minneapolis) targeting biomarkers
9 associated with ARDS outcomes (RAGE, IL-6, IL-8, IL-10, TNFR1, ST-2, fractalkine, angiopoietin-2,
10 procalcitonin and pentraxin-3), as previously described (3). We extracted microbial DNA directly from
11 samples and quantified bacterial load profiling by amplifying via quantitative polymerase chain reaction the
12 V3-V4 hypervariable region of the bacterial 16S rRNA gene as previously described (48). For fungal
13 community profiling, we sequenced amplified regions 1 and 2 of the ITS rRNA gene on the Illumina MiSeq
14 platform (Supplement).

15 Clinical classifications:

16 A consensus committee reviewed clinical and radiographic data and performed retrospective
17 classifications of the etiology and severity of acute respiratory failure. Classifications were performed
18 without knowledge of biomarker data. We retrospectively classified subjects as having ARDS per
19 established criteria (49), at risk for ARDS due to the presence of direct (pneumonia or aspiration) or indirect
20 (e.g. extra-pulmonary sepsis or acute pancreatitis) lung injury risk factors (51) but lacking ARDS diagnostic
21 criteria, acute respiratory failure without risk factors for ARDS, or acute on chronic respiratory failure. We
22 recorded clinical microbiologic results of respiratory and blood culture specimens obtained within 48hrs of
23 research sample acquisition. We excluded patients with diagnosis of IFI based on microbiologic evidence
24 and consistent clinical picture (24). We recorded antibiotic prescriptions, including beta-lactams associated
25 with false-positive BDG tests, as well as topical antifungals for skin candidiasis or oral thrush. We followed
26 patients prospectively for incidence of AKI, VFD at 30 days, and 30-day mortality.

27 Statistics

1 From baseline plasma BDG levels, we classified patients into those with a negative (≤ 60 pg/ml) or
2 positive (> 60 pg/ml) result. In sensitivity analyses, we also classified BDG levels using an 80pg/ml
3 threshold(52). Biomarker values were log-transformed for use in regression models. From available
4 biomarker and clinical variables, we classified patients into hyper-inflammatory vs. hypo-inflammatory
5 subphenotype based on an internally derived and validated parsimonious logistic regression model,
6 following application of latent class analyses (53). Baseline characteristics and outcomes between groups
7 were compared using Wilcoxon rank-sum for non-normally distributed continuous variables and Student's t-
8 test for normally distributed continuous variables. Fisher's exact was used for categorical variables. We
9 used linear regression models to examine for associations between BDG levels and biomarkers of host
10 responses. Multiple testing adjustments were implemented with the Benjamini-Hochberg method. We
11 examined for differences in BDG levels between hyper-inflammatory and hypo-inflammatory
12 subphenotypes using Wilcoxon rank sum tests. We examined for associations between BDG levels and
13 clinical outcomes with logistic regression models for AKI and 30-day mortality, zero-inflated negative
14 binomial models for VFD, and Cox-proportional hazard models for 30-day survival, adjusted for age, SOFA
15 score, subphenotype classification, beta-lactam antibiotics and batch of BDG measurement. We examined
16 for association between BDG levels and RAGE (marker of alveolar epithelial damage) using a linear
17 regression adjusted for variables potentially associated with fungal overgrowth in the airways (systemic
18 antibiotics and systemic steroids expressed as prednisone equivalent dose at the time of sampling). For the
19 association between BDG and FABP2 (marker of intestinal permeability), we built a linear regression model
20 adjusted for variables that may impact the integrity of the intestinal epithelium (receipt of vasopressors) and
21 fungal overgrowth in the gut (systemic antibiotics). For bacterial and fungal microbiota analyses, we
22 performed comparisons of microbial load (16S qPCR and N of fungal ITS reads) by BDG test results.
23 Statistical significance was defined as $p < 0.05$. All statistical analyses were performed with the R statistical
24 software, version 3.6.0 (54).

25 Study approval

26 The University of Pittsburgh Institutional Review Board approved the study (STUDY19050099) and written
27 informed consent was provided by all participants or their surrogates in accordance with the Declaration of
28 Helsinki.
29

1 Author contributions

2 **Georgios D. Kitsios:** Conceptualization, Methodology, Investigation, Software, Formal analysis, Writing -
3 Original Draft, Writing - Review & Editing, Visualization, Supervision

4 **Daniel Kotok:** Conceptualization, Methodology, Investigation, Software, Formal analysis, Writing - Original
5 Draft, Writing - Review & Editing, Visualization, Supervision

6 **Haopu Yang:** Methodology, Investigation, Writing - Review & Editing, Visualization

7 **Malcolm Finkelman:** Methodology, Investigation, Writing - Review & Editing

8 **Yonglong Zhang:** Investigation, Writing - Review & Editing

9 **Noel Britton:** Investigation, Writing - Review & Editing

10 **Rui Guo:** Investigation, Writing - Review & Editing

11 **John W. Evankovich:** Investigation, Writing - Review & Editing

12 **William Bain:** Investigation, Writing - Review & Editing

13 **Faraaz Shah:** Investigation, Writing - Review & Editing

14 **Yingze Zhang:** Investigation, Writing - Review & Editing

15 **Panayiotis V. Benos:** Methodology, Investigation, Software, Writing - Review & Editing, Visualization

16 **Bryan J. McVerry:** Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review
17 & Editing, Supervision

18 **Alison Morris:** Conceptualization, Methodology, Investigation, Writing - Original Draft, Writing - Review &
19 Editing, Supervision

20
21 Conflict of interest

22 GDK receives research funding from Karius, Inc. The other authors have no competing interests to declare.

23 MF and YZ are employed by the manufacturer of the BDG assay (Associates of Cape Cod, Inc, East
24 Falmouth, MA, USA) used in this study (“Fungitell®”).

25 Acknowledgements

26 We would like to thank all members of the research team of the Acute Lung Injury Registry (ALIR) and
27 Biospecimen Repository at the University of Pittsburgh, the medical and nursing staff in the Medical
28 Intensive Care Unit at the University of Pittsburgh Medical Center, and all patients and their families for
29 participating in this research project. Off-label use disclaimer: “Fungitell® is cleared for use as an adjunct
30 test in the diagnosis of invasive fungal disease. The data presented herein are for research purposes
31 only.”

32

33

1 Table 1: Baseline characteristics of enrolled subjects, stratified by positive and negative BDG testing. P-
 2 values from nonparametric tests comparing patients with a negative (≤ 60 pg/ml) and positive (> 60 pg/ml)
 3 BDG result are shown in bold when significant ($p < 0.05$).

	Overall	Negative	Positive	p
n	453	368	85	
Age (median [IQR])	58.3 [46.0, 67.1]	57.4 [46.5, 67.5]	59.6 [43.7, 66.2]	0.90
Male (%)	244 (53.9)	196 (53.3)	48 (56.5)	0.68
BMI (median [IQR])	28.4 [24.8, 35.7]	29.1 [24.8, 36.5]	27.5 [25.2, 32.2]	0.08
SOFA Score (median [IQR])	7 [4, 9]	6 [4, 9]	8 [5, 10]	0.01
P:F Ratio (median [IQR])	164 [117, 205]	165 [117, 206]	164 [120, 205]	0.81
History of COPD (%)	108 (23.8)	90 (24.5)	18 (21.2)	0.62
History of diabetes mellitus (%)	150 (33.1)	121 (32.9)	29 (34.1)	0.93
History of immunosuppression (%)	88 (19.4)	66 (17.9)	22 (25.9)	0.13
Group classification (%)				0.96
Acute on chronic respiratory failure	24 (5.3)	19 (5.2)	5 (5.9)	
ARDS	120 (26.5)	95 (25.8)	25 (29.4)	
At Risk for ARDS	172 (38.0)	142 (38.6)	30 (35.3)	
Control - Airway Protection	67 (14.8)	54 (14.7)	13 (15.3)	
Control - CHF	34 (7.5)	29 (7.9)	5 (5.9)	
Other	36 (7.9)	29 (7.9)	7 (8.2)	
BDG (median [IQR])	26 [15, 49]	21 [13, 33]	95 [76, 227]	<0.001
Direct injury, "pulmonary" ARDS (%)	209 (46.1)	168 (45.7)	41 (48.2)	0.76
Beta-lactam on study day 1 (%)	340 (75.7)	270 (74.2)	70 (82.4)	0.15
Topical antifungal on study day 1 (%)	13 (2.9)	9 (2.5)	4 (4.7)	0.45
Systemic antifungal on study day 1 (%)	4 (0.9)	2 (0.5)	2 (2.4)	0.34
Positive respiratory culture (%)	105 (23.2)	84 (22.8)	21 (24.7)	0.82
Incident shock (%)	226 (49.9)	178 (48.4)	48 (56.5)	0.22
Bacteremia (%)	44 (9.7)	37 (10.1)	7 (8.2)	0.76
Hyperinflammatory subphenotype (%)	127 (28.0)	89 (24.2)	38 (44.7)	<0.001

P-values from nonparametric tests comparing patients with a negative (≤ 60 pg/ml) and positive (> 60 pg/ml) BDG result are shown in bold when significant ($p < 0.05$). BMI: Body mass index, SOFA Score: Sequential organ failure assessment score, P:F Ratio: Ratio of partial pressure of arterial oxygen and fraction of inspired oxygen, COPD: Chronic obstructive pulmonary

4

5

1

2 Table 2: Associations between BDG levels and clinical outcomes. Outcomes of BDG-positive and negative
3 patients are shown in the first two columns. P-values for the statistical significance of the association
4 between BDG levels and each outcome (Logistic regression models for acute kidney injury and 30-day
5 mortality; zero-inflated negative binomial regression for ventilator-free days) are shown for unadjusted and
6 adjusted analyses (adjustments for age, sequential organ failure assessment score, hyperinflammatory
7 subphenotype assignment, beta-lactam antibiotics and batch of BDG measurement). Statistically-significant
8 associations are highlighted in bold.

9

	BDG-positive	BDG-negative	Unadjusted p-value	Adjusted p-value
Acute Kidney Injury, n (%)	63 (74%)	237 (64%)	0.008	0.10
Ventilator-free days, median (IQR)	16 (0-23)	19 (0-24)	<0.0001	0.005
30-day mortality, n (%)	34 (40%)	86 (23%)	0.001	0.01


10

11

12


1
2
3
4
5

Figure 1: Density histogram of measured 1,3-beta-D-glucan (BDG) plasma levels in a cohort of 453 critically ill patients. 19% of patients had BDG levels >60pg/ml which is the conventional threshold for a positive BDG test in the diagnostic workup of invasive fungal infection.



6
7


Figure 2: BDG levels are associated with inflammatory host-responses. A. Correlogram of 10 host-response biomarkers and BDG levels. Effect sizes of positive correlations are shown with variations of red, and statistical significance by size of circles. Comparisons were adjusted for multiple testing with the Benjamini-Hochberg method. Non-significant correlations are marked with X. B. Patients assigned to the hyperinflammatory subphenotype had significantly higher levels of BDG ($p < 0.0001$). C. Probabilistic Graphical Model analysis demonstrating first and second neighbors of the BDG variable, when considered in conjunction with 32 clinical and biomarker variables. Two first neighbors were identified: TNFR1 and ST-2. Abbreviations: IL-6: Interleukin-6; IL-10: Interleukin-10; TNFR-1: Tumor necrosis factor receptor-1; Ang-2: Angiopoietin-2; ST-2: Suppression of tumorigenicity-2; RAGE: Receptor for advanced glycation end products.



11

12

1 **Figure 3: Patients with a positive BDG test had worse 30-day survival compared to patients with**
2 **negative BDG test.** Kaplan-Meier curve for 30-day survival. Hazard ratio adjusted for age, sequential
3 organ failure assessment score, hyperinflammatory subphenotype assignment, beta-lactam antibiotics and
4 batch of BDG measurement.




6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

1
2
3
4
5


6
7
8
9

Figure 4: BDG levels are significantly associated with levels of markers of lung (A) and intestinal (B) epithelial barrier disruption. P-values of linear regression models are shown (A: effect of RAGE adjusted for systemic antibiotics and systemic steroids expressed as prednisone equivalent dose at the time of sampling; B: effect of FABP2 adjusted for receipt of vasopressors and systemic antibiotics).



1 **Figure 5: Longitudinal evolution of BDG result from baseline to 3-5 days after baseline sample and**
 2 **its association with 30-day mortality.** Patients with a negative baseline test who developed a positive
 3 test on follow-up (N = 10, 6%) and those with an initial positive test who had a subsequent negative test (N
 4 = 17, 11%) had worse 30-day mortality compared to patients who remained negative on follow-up (60% vs
 5 23% and 47% vs 23% respectively, $p < 0.05$).

6



7

Bibliography

1. Hotchkiss RS, Sherwood ER. Getting sepsis therapy right: Is decreasing inflammation or increasing the host immune response the better approach? *Science* (80-) 2015;347:1201–1202.
2. Englert JA, Bobba C, Baron RM. Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome. *JCI Insight* 2019;
3. Kitsios GD *et al.* Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for Acute Respiratory Distress Syndrome. *Crit Care Med* 2019;1.doi:10.1097/CCM.0000000000004018.
4. Sinha P *et al.* Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. *Lancet Respir Med* 2020;8:247–257.
5. Seymour CW *et al.* Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. *J Am Med Assoc* 2019;321:2003–2017.
6. Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. *Lancet Respir Med* 2017;5:524–534.
7. Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. *Cell Host Microbe* 2009;6:10–21.
8. Newton K, Dixit VM. Signaling in innate immunity and inflammation. *Cold Spring Harb Perspect Biol* 2012;4:.
9. Amornphimoltham P, Yuen PST, Star RA, Leelahavanichkul A. Gut Leakage of Fungal-Derived Inflammatory Mediators: Part of a Gut-Liver-Kidney Axis in Bacterial Sepsis. *Dig Dis Sci* 2019;64:2416–2428.
10. O'Dwyer DN *et al.* Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. *Am J Respir Crit Care Med* 2019;199:1127–1138.
11. Kitsios GD *et al.* Dysbiosis in the intensive care unit: Microbiome science coming to the bedside. *J Crit Care* 2017;38:84–91.
12. Kitsios G *et al.* *The Human Microbiome in Critical-Illness: Longitudinal Evolution of Oral, Lung and Gut Communities in Mechanically-Ventilated Patients and Association with Clinical Outcomes.* at <www.atsjournals.org>.
13. McDonald D *et al.* Extreme Dysbiosis of the Microbiome in Critical Illness. *mSphere* 2016;1:e00199-16.
14. Watkins RR *et al.* Admission to the intensive care unit is associated with changes in the oral mycobiome. *J Intensive Care Med* 2017;32:278–282.
15. Tipton L, Ghedin E, Morris A. The lung mycobiome in the next-generation sequencing era. *Virulence* 2017;8:334–341.
16. Pendleton KM *et al.* Respiratory Tract Colonization by *Candida* species Portends Worse Outcomes in Immunocompromised Patients. *Clin Pulm Med* 2018;25:197–201.
17. Delisle M-S *et al.* The clinical significance of *Candida* colonization of respiratory tract secretions in critically ill patients. *J Crit Care* 2008;23:11–17.
18. Delisle M-S *et al.* Impact of *Candida* species on clinical outcomes in patients with suspected ventilator-associated pneumonia. *Can Respir J* 2011;18:131–136.
19. Samonis G *et al.* Levofloxacin and Moxifloxacin Increase Human Gut Colonization by *Candida* Species. *Antimicrob Agents Chemother* 2005;49:5189–5189.

- 1 20. Vardakas KZ *et al.* Candidaemia: incidence, risk factors, characteristics and outcomes in
2 immunocompetent critically ill patients. *Clin Microbiol Infect* 2009;15:289–292.
- 3 21. Calabrese DR *et al.* Dectin-1 genetic deficiency predicts chronic lung allograft dysfunction and death.
4 *J Clin Invest Insight* 2019;4:.
- 5 22. Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. *Trends Mol Med*
6 2014;20:214–223.
- 7 23. Heyland D, Jiang X, Day AG, Laverdiere M. Serum β -d-glucan of critically ill patients with
8 suspected ventilator-associated pneumonia: Preliminary observations. *J Crit Care* 2011;26:536.e1-
9 536.e9.
- 10 24. Hage CA *et al.* Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary
11 and critical care practice. an official american thoracic society clinical practice guideline. *Am J Respir*
12 *Crit Care Med* 2019;200:535–550.
- 13 25. Kotok D *et al.* The evolution of radiographic edema in ARDS and its association with clinical
14 outcomes: A prospective cohort study in adult patients. *J Crit Care*
15 2020;doi:10.1016/j.jcrc.2020.01.012.
- 16 26. Ito S *et al.* False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of
17 penicillin G. *J Infect Chemother* 2018;24:812–814.
- 18 27. Mennink-Kersten MASH, Warris A, Verweij PE. 1,3- β -D-Glucan in Patients Receiving Intravenous
19 Amoxicillin–Clavulanic Acid. *N Engl J Med* 2006;354:2834–2835.
- 20 28. Sedgewick AJ, Shi I, Donovan RM, Benos P V. Learning mixed graphical models with separate
21 sparsity parameters and stability-based model selection. *BMC Bioinformatics* 2016;17:S175.
- 22 29. Sedgewick AJ *et al.* Mixed graphical models for integrative causal analysis with application to chronic
23 lung disease diagnosis and prognosis. *Bioinformatics* 2019;35:1204–1212.
- 24 30. Liu Q *et al.* IL-33-mediated IL-13 secretion by ST2+ Tregs controls inflammation after lung injury.
25 *JCI Insight* 2019;at <<https://insight.jci.org/articles/view/123919>>.
- 26 31. Shieh A, Epeldegui M, Karlamangla AS, Greendale GA. Gut permeability, inflammation, and bone
27 density across the menopause transition. *J Clin Invest Insight* 2020;5:.
- 28 32. Schorey JS, Lawrence C. The pattern recognition receptor Dectin-1: from fungi to mycobacteria. *Curr*
29 *Drug Targets* 2008;9:123–129.
- 30 33. Camilli G, Tabouret G, Quintin J. The Complexity of Fungal β -Glucan in Health and Disease: Effects
31 on the Mononuclear Phagocyte System. *Front Immunol* 2018;9:673.
- 32 34. Brown GD *et al.* Dectin-1 is a major beta-glucan receptor on macrophages. *J Exp Med*
33 2002;196:407–412.
- 34 35. Panpetch W *et al.* Gastrointestinal Colonization of *Candida Albicans* Increases Serum (1 \rightarrow 3)- β -D-
35 Glucan, without Candidemia, and Worsens Cecal Ligation and Puncture Sepsis in Murine Model.
36 *Shock* 2018;49:62–70.
- 37 36. Seider K *et al.* The Facultative Intracellular Pathogen *Candida glabrata* Subverts Macrophage
38 Cytokine Production and Phagolysosome Maturation. *J Immunol* 2011;187:3072–3086.
- 39 37. Collette JR, Zhou H, Lorenz MC. *Candida albicans* Suppresses Nitric Oxide Generation from
40 Macrophages via a Secreted Molecule. In: Chauhan N, editor. *PLoS One* 2014;9:e96203.
- 41 38. Meyer NJ, Calfee CS. Novel translational approaches to the search for precision therapies for acute
42 respiratory distress syndrome. *Lancet Respir Med* 2017;5:512–523.
- 43 39. Calfee CS *et al.* Subphenotypes in acute respiratory distress syndrome: latent class analysis of data
44 from two randomised controlled trials. *Lancet Respir Med* 2014;2:611–620.
- 45 40. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse

- 1 events: results from a meta-analysis. *Ann Allergy, Asthma Immunol* 2007;98:225–238.
- 2 41. Yoshida M *et al.* Detection of plasma (1 --> 3)-beta-D-glucan in patients with Fusarium,
3 Trichosporon, Saccharomyces and Acremonium fungaemias. *J Med Vet Mycol* 35:371–4.
- 4 42. Kitsios GD *et al.* Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at
5 Risk for Acute Respiratory Distress Syndrome. *Crit Care Med* 2019;47:1724–1734.
- 6 43. Mrozek S *et al.* Elevated Plasma Levels of sRAGE Are Associated With Nonfocal CT-Based Lung
7 Imaging in Patients With ARDS: A Prospective Multicenter Study. *Chest* 2016;150:998–1007.
- 8 44. Leelahavanichkul A *et al.* Gastrointestinal Leakage Detected by Serum (1→3)-β-D-Glucan in Mouse
9 Models and a Pilot Study in Patients with Sepsis. *SHOCK* 2016;46:506–518.
- 10 45. Deitch EA. Gut-origin sepsis: evolution of a concept. *Surg* 2012;10:350–356.
- 11 46. Nagasawa K *et al.* Experimental proof of contamination of blood components by (1?3)-?-D-glucan
12 caused by filtration with cellulose filters in the manufacturing process. *J Artif Organs* 2003;6:49–54.
- 13 47. Kanda H *et al.* Influence of various hemodialysis membranes on the plasma (1→3)-β-D-glucan level.
14 *Kidney Int* 2001;60:319–323.
- 15 48. Kitsios GD *et al.* Respiratory Microbiome Profiling for Etiologic Diagnosis of Pneumonia in
16 Mechanically Ventilated Patients. *Front Microbiol* 2018;9:1413.
- 17 49. Fair K *et al.* Rectal Swabs from Critically Ill Patients Provide Discordant Representations of the Gut
18 Microbiome Compared to Stool Samples. *mSphere* 2019;4:e00358-19.
- 19 50. 1,3-beta-D-glucan Fungitell ®. at <[https://www.fungitell.com/pdfs/Fungitell_Brochure_PR18-](https://www.fungitell.com/pdfs/Fungitell_Brochure_PR18-016web.pdf)
20 016web.pdf>.
- 21 51. Neto AS *et al.* Epidemiological characteristics, practice of ventilation, and clinical outcome in patients
22 at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT):
23 an international, multicentre, prospective study. *Lancet Respir Med* 2016;4:882–893.
- 24 52. Caporaso JG *et al.* Ultra-high-throughput microbial community analysis on the Illumina HiSeq and
25 MiSeq platforms. *ISME J* 2012;6:1621–1624.
- 26 53. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics
27 of microbiome census data. *PLoS One* 2013;8:e61217.
- 28 54. R Core Team. R: A Language and Environment for Statistical Computing. 2018;at <[https://www.r-](https://www.r-project.org/)
29 project.org/>.
- 30
- 31
- 32